Drugs / DF01
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04000438 | Jun 2019 → Feb 2023 | — | Dilafor AB | Completed | No outcome recorded |
| Phase 2 | NCT03001193 | Dec 2016 → Nov 2018 | dystocia | Dilafor AB | Completed | No outcome recorded |
| Phase 2 | NCT00710242 | Apr 2007 → Mar 2009 | pregnancy disorder | Dilafor AB | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DF01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04000438 ↗ |
| Known as | tafoxiparin | “Tafoxiparin, a novel drug candidate for cervical ripening and labor augmentation: results from 2 randomized, placebo-controlled studies.” PMID 38462256 ↗ May 20231“tafoxiparin” NCT04000438 ↗ |
| Modality | Other / unclassified | “Tafoxiparin is a depolymerized form of heparin with a molecular structure that eliminates the anticoagulant effects of heparin.” PMID 38462256 ↗ May 2023 |
| Route | Subcutaneous | “In study 1, patients at 38 to 40 weeks of gestation received 60 mg tafoxiparin or placebo daily as 0.4 mL subcutaneous injections until labor onset (maximum 28 days).” PMID 38462256 ↗ May 2023 |